 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...4243444546474849505152...266267» |
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis. (On Demand | S406; Poster Bd # 279) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2596;
Incorporating baseline biomarkers like the IFN-? signature algorithm in neoadjuvant treatment decisions will optimize the risk-benefit ratio for these pts.
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
The DIET study: A randomized controlled trial of a high fiber diet in cancer patients (pts) receiving immune checkpoint blockade (ICB). (On Demand | Hall A; Poster Bd # 363b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2582;
P2
14 treated with PD1 monotherapy, 9 with ipilimumab + nivolumab, and 1 with nivolumab + relatlimab. Clinical trial information: NCT04645680.
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM). (On Demand | Hall A; Poster Bd # 361b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2579;
P2
Long-term outcomes of the CheckMate 204 study combining ipilimumab (ipi) (3mg/kg) plus nivo (1 mg/kg) for asymptomatic MBM reported an intracranial (IC) response in 54% of pts...Longitudinal research blood, tissue, and microbiome samples will be collected along with neurocognitive assessment and quality of life surveys. Clinical trial information: NCT05704647.
- A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000. (On Demand | Hall A; Poster Bd # 360b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2577;
P2
In the Checkmate-204 trial of ipilimumab with nivolumab in MBM, the 6-month progression free survival (PFS) rate was 19% with a median PFS of only 1.2 months in symptomatic participants (those with neurological symptoms including steroids up to 4 mg/day of dexamethasone, n=18)...The single-arm phase 2 TRICOTEL study explored the triplet regimen of vemurafenib + cobimetinib + atezolizumab in MBM; in the symptomatic brain met cohort, 6-month PFS was 57% (n=24)...Funding: NIH/NCI grants U10CA180888, U10CA180819, U10CA180820 U10CA180868; and in part by Pfizer, Inc. Clinical trial information: NCT04511013.
- OMNIA-1: A phase I/II study, an IL-2R-?? targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti?PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma. (On Demand | Hall A; Poster Bd # 358b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2573;
P1/2
Clinical trial information: NCT04511013. Recombinant IL-2 (proleukin) induces durable responses in approximately 10% of patients with melanoma...In Part 3, the efficacy and safety of ANV419 in combination with the approved doses pembrolizumab or ipilimumab will be evaluated using a Simon
- Keytruda (pembrolizumab) / Merck (MSD), Kimmtrak (tebentafusp) / Immunocore
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM). (On Demand | Hall A; Poster Bd # 356a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2568;
P2/3
Nat Med 28:2364-2373, 2022. Clinical trial information: NCT05549297.
- Yervoy (ipilimumab) / Ono Pharma, BMS
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma. (On Demand | Hall A; Poster Bd # 351) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2562;
P1
Further analyses are underway to evaluate T cell trafficking and persistence. Clinical trial information: NCT03068624.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma. (On Demand | Hall A; Poster Bd # 348) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2559;
One patient,who had G3 colitis (with the need of infliximab), had 32% of reduction in maximum SUV but 100% of viable tumor cells on pathological report. FGD-PET/CT may help to predict pathological response in patients with clinical stage III melanoma who undergo to neoadjuvant nivolumab and ipilimumab.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
[18F]FDG-PET to identify pathological responses upon neoadjuvant immune checkpoint blockade in cutaneous squamous cell carcinoma. (On Demand | Hall A; Poster Bd # 347) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2558;
P2
FGD-PET/CT may help to predict pathological response in patients with clinical stage III melanoma who undergo to neoadjuvant nivolumab and ipilimumab. Background: To improve clinical prospects of patients with locally advanced cutaneous SCC (CSCC), we tested the efficacy of neoadjuvant nivolumab with or without ipilimumab prior to standard of care curative surgery
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in CheckMate 238. (On Demand | Hall A; Poster Bd # 340) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2551;
P3
Incorporation of ctDNA with other tumor molecular features may improve prediction of RFS and DMFS in this setting. Clinical trial information: NCT02388906.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma. (On Demand | Hall A; Poster Bd # 326) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2538;
P2
TRAE profile was similar to prior reports. Biomarker analyses are planned to identify patient profiles associated with particular benefit from this regimen.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma. (On Demand | Hall A; Poster Bd # 321) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2533;
P2
This data warrants further investigation in independent cohorts and into the potential effect of pharmacological and psychosocial interventions, e.g. adrenergic receptor blockade, on the anti-tumor immune response and patient outcomes. Clinical trial information: NCT02977052.
- Yervoy (ipilimumab) / Ono Pharma, BMS
High dose ipilimumab (Ipi) plus temozolomide (TMZ) after progression on standard or low dose Ipi in advanced melanoma. (On Demand | Hall A; Poster Bd # 320) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2532;
Ipi10+TMZ demonstrated efficacy including dramatic responses in pts with advanced melanoma refractory to standard or low doses of Ipi + anti-PD1, even with CNS metastases. Molecular data suggest a potential threshold of Ipi dose for activation of sufficient anti-tumor immune response, and higher dose Ipi is required for some pts.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Melanomas lacking HLA class I expression and response to checkpoint inhibitor. (On Demand | Hall A; Poster Bd # 316) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2530;
Responses were to ipilimumab (ipi) (N=2) and ipi/nivolumab (N=1). One pt responding to ipi had progressed on pembrolizumab; the other 2 responders were treatment-na
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD). (On Demand | Hall A; Poster Bd # 315) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2529;
Similar outcomes between the NIVO cohorts support the ITC methodology. Results should be interpreted with caution given differences in study design and changes in treatment landscape over time.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ?3y on nivolumab (NIVO) (Available On Demand; Poster Bd # 305) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2519;
P3
3y may allow the burden of imaging and follow-up visits to be reduced in this group. Clinical trial information: NCT01844505.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Immune infiltrates in metastatic uveal melanoma liver metastases and associations with clinical outcomes. (On Demand | Hall A; Poster Bd # 301) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2515;
OS did not significantly improve with the presence of any lymphocytes, TILs, CD8+ T cells, or with the absence of FoxP3+ T cells. These results were consistent across all patients whether they were treated with ICIs or not.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
A phase I, randomized, controlled, multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM 2 trial). (On Demand | Hall A; Poster Bd # 296) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2510;
P1
The efficacy of this combination treatment is encouraging, however, one cycle of neoadjuvant IPI3/NIVO1 given before IHP did not seem beneficial, neither in regards to safety nor efficacy. Clinical trial information: NCT04463368.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
A prediction model for response to immune checkpoint inhibition in advanced melanoma. (On Demand | Hall A; Poster Bd # 295) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2509;
We present a model based on both clinical variables and primary melanoma characteristics capable of predicting response to ICI in patients with advanced melanoma. This model can discriminate between patients with a very good and very poor prognosis.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma. (On Demand | Hall A; Poster Bd # 288) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2502;
P1/2
The median PFS, 12 month PFS and ORR for nivo-deno and ipi-nivo-deno are encouraging compared with CHECKMATE 067. Clinical trial information: NCT03161756.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma. (On Demand | Hall A; Poster Bd # 286) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2500;
P3
Our results show the reproducibility of our previously developed algorithm in predicting response in patients with advanced metastatic melanoma. The inability of the model to predict recurrence in patients treated in the adjuvant setting might reflect the difference in the endpoint tested (response versus recurrence), which requires further training on larger datasets for this particular endpoint prediction, and/or the limited tumor volume in resected disease below a threshold that machine learning can predict a difference.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609). (Live Stream | Arie Crown Theater) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2464;
Our results suggest that similar to results among patients who received chemotherapy there is a linear correlation with PFS and OS. As a consequence, the thresholds for RECIST categories do not correspond to thresholds in patient outcomes.
- SD-101 / TriSalus Life Sci, UT MD Anderson Cancer Center
Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM). (On Demand | S100bc; Poster Bd # 363) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2449;
P1
As a consequence, the thresholds for RECIST categories do not correspond to thresholds in patient outcomes. The study consists of dose-escalation cohorts of SD-101 alone (Cohort A), with nivolumab (Cohort B), or nivolumab + ipilimumab (Cohort C)...Only 3 patients were treatment-na
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study. (On Demand | Hall A; Poster Bd # 511a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2439;
Su. Clinical trial information: ECTR2022-502101-15-00.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population. (On Demand | Hall A; Poster Bd # 504) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2427;
This signals the need for closer monitoring, early recognition, and management of irAEs in these pts. In addition, pts who developed irAEs were more likely to experience partial or complete response in a diverse tumor cohort.
- Yervoy (ipilimumab) / Ono Pharma, BMS
Immune-related adrenal insufficiency: A single center retrospective analysis. (On Demand | Hall A; Poster Bd # 501) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2424;
Detection of irAI before clinical presentation let us prevent severe consequences including life threating. We consider that routine cortisol assessment during immunotherapy should be implemented in clinical practice.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Development of a novel immune-related toxicity grading system for predicting outcomes in patients with solid tumours treated with immune checkpoint inhibitors (ICI). (On Demand | Hall A; Poster Bd # 486) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2409;
Further prospective evaluation and correlation to translational secondary endpoints with immunological phenotyping is ongoing. External validation is warranted to support further use of OST in routine clinical practice.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
The study of immune-related adverse events in a community-based centre. (On Demand | Hall A; Poster Bd # 484) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2407;
In our study population consisting mostly of AA and Hispanics, the rate of IrAE of any grade as well as grade 3 or 4 IrAE with ICI therapy was comparable to what was seen in clinical trials involving these drugs. This data and its potential effects on survival outcomes need to be analyzed in prospective studies involving a larger number of patients.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Multisystem immune-related adverse events from dual agent immunotherapy use. (On Demand | Hall A; Poster Bd # 477) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2400;
Many patients experienced debilitating associated symptoms and hospital admission relating to irAEs. It is important for both the counselling and consent of patients, and for patient education, to discuss the possibility of multiple irAEs prior to dual immunotherapy initiation.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
The differential response to immune checkpoint inhibitors (ICIs) according to mismatch repair alterations in gastrointestinal (GI) non-colorectal cancers (non-CRCs) and the impact of dual vs. monotherapy ICIs on survival in GI (CRC and non-CRC) cancers. (On Demand | Hall A; Poster Bd # 462) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2386;
In ICI-treated GI (CRC and non-CRC) patients with MutL co-loss, there was a trend for better survival with ipi/nivo compared to pembro. Our data suggest that the MutS vs.
- lefitolimod (MGN1703) / OncXerna Therap, iPharma, Gilead, Yervoy (ipilimumab) / Ono Pharma, BMS
Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial. (On Demand | Hall A; Poster Bd # 406) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2332;
The combination of high subcutaneous doses or intra-tumoral administration of lefitolimod in combination with ipilimumab is safe and well tolerated in patients with advanced cancers, with preliminary antitumor activity observed. Clinical trial information: NCT0266877.
- Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis. (On Demand | Hall A; Poster Bd # 404) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2330;
Our findings are consistent with established circadian mechanisms that control immune cell functions and trafficking over a 24-h period. Prospective randomized trials are warranted to establish ICI timing recommendations for optimizing treatment efficacy in patients with different cancer types and at minimal cost.
- Opdivo (nivolumab) / Ono Pharma, BMS, 800 TCR - T / Cure Biosci, Yervoy (ipilimumab) / Ono Pharma, BMS
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC). (On Demand | Hall A; Poster Bd # 391) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2317;
P1
The manufacturing method utilized produced large numbers of highly purified CD8+ HERV-E reactive T-cells that were not associated with any dose limiting toxicities when given at doses up to 5x107 cells/kg. For pts in DL4, HERV-E TCR were observed to proliferate in vivo, traffic to a metastatic site, and induce tumor regression in one mccRCC pts.
- ragifilimab (INCAGN1876) / Incyte
A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers. (On Demand | Hall A; Poster Bd # 383) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2310;
P1/2
No novel safety signals were seen. INCAGN01876 300 mg Q2W was selected as RP2D based on safety and preliminary PK/PD data and used for expansion in combination with NIVO or IPI.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
A phase II basket trial of dual anti (On Demand | S100bc; Poster Bd # 211) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2281;
P2
Correlative studies to determine response and resistance markers are ongoing. Expanded prospective studies exploring the role of immunotherapy in vulvar cancers are warranted.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. (On Demand | Hall A; Poster Bd # 243) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2188;
P2
However, given 22% of pts had PR (2 with >1 year duration) in this heavily pretreated cohort, additional study may be warranted to further evaluate efficacy. Clinical trial information: NCT02693535.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study. (Live Stream | Hall D1) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2155;
P=N/A
The 82.5% CR rate on primary tumor 6 months post RTCT suggests favorable clinical outcomes. Clinical trial information: NCT04256213.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial. (Live Stream | Hall D1) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2143;
P3
6 cycles) and discontinuation for low-grade AEs may have contributed to the lack of DFS benefit observed in CheckMate 914 part A. Clinical trial information: NCT03138512. >CI, confidence interval; HR, hazard ratio.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh). (Available On Demand; Poster Bd # 12) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2133;
P2
An additional cohort of 20 pts is enrolling with Cabo starting dose of 20 mg daily. Clinical trial information: NCT04413123.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer. (On Demand | Hall A; Poster Bd # 95b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2106;
P2
2019. Clinical trial information: EudraCT 2021-005364-22.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
Association of 18F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies. (On Demand | Hall A; Poster Bd # 92) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2100;
54pts were treated with single agent cabozantinib (cabo) on a phase II trial and 47 pts were treated with cabozantinib and nivolumab, with or without ipilimumab (cabonivo +/- ipi), on a phase I trial... The TRAQinform Profile analysis of 18F-FDG PET scans provided both prognostic and predictive information for patients with metastatic GU malignancies treated with either cabo or cabonivo +/- ipi.
- Bavencio (avelumab) / EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB). (On Demand | Hall A; Poster Bd # 90) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2098;
Trends towards longer PFS and OS with high fiber intake were observed among pts with mRCC. Analyses of the gut microbiome are underway to investigate mechanisms of action.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Association between intra-tumoral microbiome and clinical benefit (CB) from immunotherapy (IO) in patients with metastatic renal cell carcinoma (mRCC). (On Demand | Hall A; Poster Bd # 53) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2062;
In line with gut microbiome studies, an increased intra-tumoral Shannon diversity index was also associated with CB to IO in our 1st line cohort, further suggesting that bacterial diversity could be a driver of response. Additionally, several genera associated with CB are particularly relevant.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM-588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC). (On Demand | Hall A; Poster Bd # 48) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2057;
P1
These observations, combined with alterations in serum cytokines, provide biologic rationale for the clinical activity seen with CBM588 in combination with nivolumab/ipilimumab in this trial. Clinical trial information: NCT03829111.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Response to immune checkpoint inhibitor (ICI) rechallenge in patients with metastatic renal cell carcinoma who progressed on prior ICI: A systematic review and meta-analysis. (On Demand | Hall A; Poster Bd # 39) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2048;
Therefore, it provides strong clinical rationale to consider rechallenging with ICI-based therapy for later-line treatment of mRCC patients who have progressed on prior ICI. >*Studies were excluded because DCR was not reported.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma. (On Demand | Hall A; Poster Bd # 37) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2046;
Interaction test did not suggest a significant advantage for IO/IO or TKI/IO for mutation-present or -absent groups. Clinical stratification remains key for selecting TKI/IO or IO/IO for patients.
- Global circulating free DNA methylation and fragmentome deconvolution in patients with metastatic renal cell carcinoma treated with immunotherapy (GOLDEN). (On Demand | Hall A; Poster Bd # 36) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2045;
P=N/A
We found several trends and one significant association between these signatures and pt outcomes, which support further validation in larger cohorts. Clinical trial information: NCT03702309.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC). (On Demand | Hall A; Poster Bd # 30) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2039;
We were unable to identify predictors of 2L therapy initiation. Attrition rates between lines of therapy have important implications for patient counseling, cost analyses, and clinical trial design.
- Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States. (On Demand | Hall A; Poster Bd # 24) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2033;
P+A is also associated with fewer post-treatment hospitalizations. We argue that the higher toxicity of N+I may explain its lower short-term effectiveness and may also explain its lower effectiveness in patients with favorable risk.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC). (Live Stream | Hall D1; Poster Bd # 150) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2013;
P2
Lower MPR rates were observed for pts with KRAS+ tumors. STK11 mut and KRAS+STK11+ co-mut status both trended toward shorter RFS, though definitive conclusions are limited by cohort size and treatment heterogeneity.